Company Filing History:
Years Active: 2016-2018
Title: Marc Maria Pierre Vandermeeren: Innovator in Monoclonal Antibodies
Introduction
Marc Maria Pierre Vandermeeren is a notable inventor based in Geel, Belgium. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His work focuses on innovative solutions for therapeutic applications.
Latest Patents
Vandermeeren holds 2 patents related to N-11 truncated amyloid-beta monoclonal antibodies. His first patent, titled "N-11 truncated amyloid-beta monoclonal antibodies, compositions, methods and uses," pertains to antibodies that are specific for the human Amyloid-beta_11 N-terminal site, known as Aβ11-x peptides. This invention includes methods for making and using these antibodies, which encompass therapeutic formulations, administration, and devices. The second patent, "N-11 truncated amyloid-beta Aβ11-x monoclonal antibodies and compositions," similarly focuses on antibodies specific for the human Amyloid-beta 11 N-terminal site, providing additional methods for their application in therapeutic contexts.
Career Highlights
Vandermeeren is currently associated with Janssen Pharmaceutica NV, a leading pharmaceutical company known for its innovative research and development in healthcare. His work at Janssen has allowed him to contribute to advancements in medical treatments and therapies.
Collaborations
One of his notable collaborators is Marc Mercken, with whom he has worked on various projects related to monoclonal antibodies and their applications in medicine.
Conclusion
Marc Maria Pierre Vandermeeren is a distinguished inventor whose work in monoclonal antibodies has the potential to impact therapeutic practices significantly. His patents reflect a commitment to advancing medical science and improving patient care.